The most common considerations PCP selected for insulin continuation or intensification were the degree of hyperglycemia/HbA1c levels (95.8%), patient compliance with existing regimen (80.3%), the risk of hypoglycemia (45.1%) and whether the patient was willing to increase insulin doses (36.6%). This evidence concerns the gene INS and Hypoglycemia.